Stifel Nicolaus Issues Pessimistic Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its price objective reduced by equities research analysts at Stifel Nicolaus from $190.00 to $175.00 in a report issued on Monday,Benzinga reports. The firm presently has a "hold" rating on the stock. Stifel Nicolaus' price target would suggest a potential upside of 10.08% from the stock's current price.

Several other research firms have also issued reports on INSP. KeyCorp lowered their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a report on Monday. Piper Sandler lowered their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Wells Fargo & Company cut their target price on Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Robert W. Baird lowered their price target on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating for the company in a research report on Tuesday, February 11th. Finally, Morgan Stanley dropped their price target on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $218.90.

Inspire Medical Systems Stock Performance

Shares of INSP traded up $0.77 on Monday, reaching $158.97. The stock had a trading volume of 315,939 shares, compared to its average volume of 583,912. Inspire Medical Systems has a 12-month low of $123.00 and a 12-month high of $257.40. The firm has a market capitalization of $4.73 billion, a price-to-earnings ratio of 91.89, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39. The company has a 50-day simple moving average of $162.86 and a 200-day simple moving average of $181.43.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, analysts expect that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In related news, insider Randy Ban sold 25,584 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the sale, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO John Rondoni sold 583 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares in the company, valued at $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.10% of the company's stock.

Institutional Trading of Inspire Medical Systems

Several hedge funds have recently bought and sold shares of INSP. Smartleaf Asset Management LLC raised its stake in shares of Inspire Medical Systems by 178.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock worth $66,000 after buying an additional 229 shares during the period. Merit Financial Group LLC bought a new stake in Inspire Medical Systems during the 4th quarter worth approximately $313,000. Jennison Associates LLC bought a new stake in Inspire Medical Systems during the 4th quarter worth approximately $8,821,000. Janney Montgomery Scott LLC lifted its holdings in Inspire Medical Systems by 248.5% during the fourth quarter. Janney Montgomery Scott LLC now owns 4,806 shares of the company's stock valued at $891,000 after purchasing an additional 3,427 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Inspire Medical Systems in the fourth quarter worth approximately $292,000. Institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.